NASDAQ:ESPR - Esperion Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Esperion Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $68.35 -2.19 (-3.10 %) (As of 02/20/2020 04:00 PM ET) Add Compare Today's Range$66.31Now: $68.35▼$71.1950-Day Range$49.10MA: $59.95▼$73.8452-Week Range$33.13Now: $68.35▼$76.98Volume940,400 shsAverage Volume651,941 shsMarket Capitalization$1.87 billionP/E RatioN/ADividend YieldN/ABeta2.13 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ESPR Previous Symbol CUSIPN/A CIK1434868 Webhttp://www.esperion.com/ Phone734-887-3903Debt Debt-to-Equity Ratio0.01 Current Ratio4.41 Quick Ratio4.41Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.95 per share Price / Book23.17Profitability EPS (Most Recent Fiscal Year)($7.54) Net Income$-201,810,000.00 Net MarginsN/A Return on Equity-84.30% Return on Assets-40.36%Miscellaneous Employees76 Outstanding Shares27,327,000Market Cap$1.87 billion Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive ESPR News and Ratings via Email Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ESPR Rates by TradingView Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions What is Esperion Therapeutics' stock symbol? Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR." How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics Inc (NASDAQ:ESPR) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($2.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by $0.42. The biopharmaceutical company earned $0.98 million during the quarter, compared to analyst estimates of $0.99 million. During the same quarter last year, the company posted ($1.86) EPS. View Esperion Therapeutics' Earnings History. When is Esperion Therapeutics' next earnings date? Esperion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Esperion Therapeutics. What price target have analysts set for ESPR? 10 Wall Street analysts have issued 12 month price targets for Esperion Therapeutics' shares. Their forecasts range from $45.00 to $90.00. On average, they expect Esperion Therapeutics' stock price to reach $70.44 in the next year. This suggests a possible upside of 3.1% from the stock's current price. View Analyst Price Targets for Esperion Therapeutics. What is the consensus analysts' recommendation for Esperion Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Esperion Therapeutics. What are Wall Street analysts saying about Esperion Therapeutics stock? Here are some recent quotes from research analysts about Esperion Therapeutics stock: 1. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and lowering our target price to $70 which reflects a more conservative pre-CVOT BPA/combo sales ramp and higher SG&A assumptions. Even with our more conservative forecasts, we believe ESPR is undervalued at these levels (EV of ~$700 million) as we think the stock continues to reflect investor skepticism on the commercial opportunity for BPA/ combo and the company’s cash runway. We view BPA/combo as a clinically de-risked asset with two upcoming and believe BPA’s CVOT design portends a high probability of success. Further, our recent KOL checks have been consistent with our past discussions (see deep dive) in validating what we believe is a meaningful commercial opportunity for BPA/combo in the statin intolerant population." (9/17/2019) 2. Northland Securities analysts commented, "We are now modeling $0.69 in non-GAAP EPS on $97.8 million in revenue for FY/19." (8/29/2019) 3. Chardan Capital analysts commented, "We find the relevant statistical analyses in the NEJM publications roughly consistent with those of our consulted biostatisticians and still see the following open issues as unresolved:." (3/14/2019) Has Esperion Therapeutics been receiving favorable news coverage? Press coverage about ESPR stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Esperion Therapeutics earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Esperion Therapeutics. Who are some of Esperion Therapeutics' key competitors? Some companies that are related to Esperion Therapeutics include Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), FibroGen (FGEN) and GW Pharmaceuticals PLC- (GWPH). What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include Alon USA Partners (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), Ship Finance International (SFL), NVIDIA (NVDA), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), NXP Semiconductors (NXPI), Puma Biotechnology (PBYI) and Gilead Sciences (GILD). Who are Esperion Therapeutics' key executives? Esperion Therapeutics' management team includes the folowing people: Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)Mr. Alexander Duke Schwartz, Sr. Director of Investor RelationsMs. Marianne Andreach, Sr. VP Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.03%), Credit Suisse AG (3.25%), Rhenman & Partners Asset Management AB (2.42%), Goldman Sachs Group Inc. (1.49%), Geode Capital Management LLC (1.27%) and Amundi Pioneer Asset Management Inc. (1.20%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics. Which institutional investors are selling Esperion Therapeutics stock? ESPR stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., State Street Corp, Credit Suisse AG, Rafferty Asset Management LLC, Spark Investment Management LLC, Oxford Asset Management LLP, Alliancebernstein L.P. and Charles Schwab Investment Management Inc.. Company insiders that have sold Esperion Therapeutics company stock in the last year include Nicole Vitullo, Richard Bartram and Roger S Newton. View Insider Buying and Selling for Esperion Therapeutics. Which institutional investors are buying Esperion Therapeutics stock? ESPR stock was purchased by a variety of institutional investors in the last quarter, including Rothschild & Co. Asset Management US Inc., Candriam Luxembourg S.C.A., Moody Aldrich Partners LLC, Goldman Sachs Group Inc., AXA, Sei Investments Co., Man Group plc and Pinnacle Associates Ltd.. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics. How do I buy shares of Esperion Therapeutics? Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Esperion Therapeutics' stock price today? One share of ESPR stock can currently be purchased for approximately $68.35. How big of a company is Esperion Therapeutics? Esperion Therapeutics has a market capitalization of $1.87 billion. The biopharmaceutical company earns $-201,810,000.00 in net income (profit) each year or ($7.54) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe.View Additional Information About Esperion Therapeutics. What is Esperion Therapeutics' official website? The official website for Esperion Therapeutics is http://www.esperion.com/. How can I contact Esperion Therapeutics? Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected] MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 532 (Vote Outperform)Underperform Votes: 417 (Vote Underperform)Total Votes: 949MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: Why are analyst ratings important in trading stocks?
